Adaptive Biotechnologies Corporation
ADPT
$7.11
-$0.30-4.05%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 178.96M | 177.28M | 168.77M | 174.50M | 170.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 178.96M | 177.28M | 168.77M | 174.50M | 170.28M |
| Cost of Revenue | 67.98M | 59.32M | 66.37M | 66.33M | 69.31M |
| Gross Profit | 110.98M | 117.96M | 102.39M | 108.18M | 100.96M |
| SG&A Expenses | 157.57M | 160.57M | 163.33M | 171.29M | 172.51M |
| Depreciation & Amortization | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 334.30M | 344.43M | 354.24M | 367.68M | 371.88M |
| Operating Income | -155.34M | -167.15M | -185.47M | -193.18M | -201.61M |
| Income Before Tax | -159.60M | -195.35M | -213.57M | -215.14M | -225.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -159.60 | -195.35 | -213.57 | -215.14 | -225.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 103.00K | 104.00K | 104.00K | 79.00K | 54.00K |
| Net Income | -159.49M | -195.24M | -213.47M | -215.06M | -225.25M |
| EBIT | -155.34M | -167.15M | -185.47M | -193.18M | -201.61M |
| EBITDA | -136.09M | -146.95M | -164.10M | -171.15M | -179.38M |
| EPS Basic | -1.09 | -1.34 | -1.47 | -1.48 | -1.56 |
| Normalized Basic EPS | -0.66 | -0.72 | -0.80 | -0.84 | -0.88 |
| EPS Diluted | -1.09 | -1.34 | -1.47 | -1.48 | -1.56 |
| Normalized Diluted EPS | -0.66 | -0.72 | -0.80 | -0.84 | -0.88 |
| Average Basic Shares Outstanding | 588.40M | 585.62M | 582.81M | 579.79M | 577.51M |
| Average Diluted Shares Outstanding | 588.40M | 585.62M | 582.81M | 579.79M | 577.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
